• Explore /
  • Poster
  • / Association between patient-reported outcomes (PROs) and changes in prostate-specific antigen (PSA) in patients (pts) with advanced prostate cancer treated with apalutamide (APA) in the SPARTAN and TITAN studies.

Association between patient-reported outcomes (PROs) and changes in prostate-specific antigen (PSA) in patients (pts) with advanced prostate cancer treated with apalutamide (APA) in the SPARTAN and TITAN studies.

Abstract Video & Slides Poster

Authors

Eric Small

Eric Jay Small

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA

Eric Jay Small , Kim N. Chi , Simon Chowdhury , Katherine B. Bevans , Amitabha Bhaumik , Fred Saad , Byung Chung , Lawrence Ivan Karsh , Stephane Oudard , Peter De Porre , Sabine D. Brookman-May , Sharon Anne McCarthy , Suneel Mundle , Hirotsugu Uemura , Matthew Raymond Smith , Neeraj Agarwal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care

Clinical Trial Registration Number

NCT02489318 (TITAN); NCT01946204 (SPARTAN)

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 73)

DOI

10.1200/JCO.2022.40.6_suppl.073

Abstract #

73

Poster Bd #

D1

Abstract Disclosures

Similar Posters

First Author: Kim N. Chi

First Author: Stephen J. Freedland

First Author: Michael Durkin

First Author: Gordon Andrew Brown